Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer
1989; Elsevier BV; Volume: 35; Issue: 3 Linguagem: Inglês
10.1016/0090-8258(89)90081-4
ISSN1095-6859
AutoresKiichiro Noda, Kensaku Teshima, K Tekeuti, Kazuo Hasegawa, Kinya Inoue, Kazuhiko Yamashita, I Sawaragi, Tokuro Nakajima, E Takashima, M Ikeuchi, K Sekiba, Hiroyuki Okuda, M Ichijo, Tsuneo Saito, Mitsuru Ozawa, Hiroyuki Tamura, Tsutomu Chihara, Kazuo Kuzuya, Masami Ozaki, Minoru Inagaki, Suketami Tominaga,
Tópico(s)Colorectal and Anal Carcinomas
ResumoThe efficacy of immunotherapy using a streptococcal preparation, OK-432, was evaluated in each clinical stage of uterine cervical cancer. The 382 eligible patients were stratified by clinical stage and presence/absence of surgery. Within each stratum, patient's were randomly allocated to OK-432 treatment or to control treatment. OK-432 significantly inhibited recurrence in patients with stage II cervical cancer; the recurrence-free interval and survival time were remarkably prolonged in patients with stage II disease who underwent surgery. However, OK-432 did not significantly prolong these parameters in patients with stage III disease. Retrospective analyses revealed that in patients with or without lymph node metastases who underwent surgery, the recurrence-free interval and survival time were significantly prolonged by OK-432 treatment. These results indicate that OK-432 is an effective and useful postoperative immunotherapeutic agent for uterine cervical cancer.
Referência(s)